Assessment of Feasibility and Safety of a Polymeric Medical Device with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Knee Femoral Cartilage Lesions

The primary objective of this study is to evaluate the **feasibility** and **safety** of a combined advanced therapy medicinal product, which integrates a polymeric medical device with autologous bone marrow-derived mesenchymal stem cells in a hydrogel mixture, for the treatment of isolated lesions in the knee femoral cartilage. This assessment is clinically relevant as it aims to address the therapeutic potential and safety profile of this innovative treatment approach, which could offer a novel solution for patients suffering from these specific cartilage lesions.

The clinical trial involves participants diagnosed with **knee femoral cartilage isolated lesions**. The study population includes both male and female subjects, with an age range categorized as adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed. The selection process for the trial population remains unspecified.

The clinical trial is designed to assess the feasibility and safety of a combined advanced therapy medicinal product for the treatment of **knee femoral cartilage isolated lesions**. This trial is structured as a Phase 1 study, which will be conducted over an estimated duration from September 1, 2024, to August 31, 2027. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group or the control group, with neither the participants nor the investigators aware of the group assignments, thereby minimizing bias.

The sequence of study visits begins with an inclusion (screening) visit, where potential participants will be evaluated against the inclusion and exclusion criteria to determine eligibility. Following successful screening, participants will undergo baseline assessments before the initiation of the treatment. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status, assess the treatment's efficacy, and record any adverse events. These follow-up visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the long-term effects of the treatment.

The expected length of participant involvement in the trial is approximately three years, aligning with the overall trial duration. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the safety of the participants and the integrity of the data collected.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is available from the provided data. Consequently, a detailed description of the experimental treatment cannot be provided.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Therefore, a description of these elements is not possible based on the current data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. As such, these aspects cannot be detailed in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on September 1, 2024, with an estimated completion date of August 31, 2027. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a combination of clinical observations and laboratory tests to gather initial efficacy data. The data collection and analysis will adhere to standard clinical trial protocols, ensuring rigorous and systematic evaluation of any observed therapeutic effects. The trial will employ validated methods and instruments appropriate for the investigational product and the condition under study, although these are not specified in the available data.